The effects of Beinaglutide on obesity and related factors: a systematic review and meta-analysis of randomized controlled trials.

IF 2.7 Q3 ENDOCRINOLOGY & METABOLISM

Expert Review of Endocrinology & Metabolism Pub Date : 2025-04-11 DOI:10.1080/17446651.2025.2491404

Sepideh Poshtdar, Pejman Rohani, Amirali Ahrabi, Nekoo Panahi, Mohammad Hassan Sohouli

{"title":"The effects of Beinaglutide on obesity and related factors: a systematic review and meta-analysis of randomized controlled trials.","authors":"Sepideh Poshtdar, Pejman Rohani, Amirali Ahrabi, Nekoo Panahi, Mohammad Hassan Sohouli","doi":"10.1080/17446651.2025.2491404","DOIUrl":null,"url":null,"abstract":"Background: Considering the important role of obesity and related factors in different societies on increasing the burden of non-communicable diseases, in this review we will investigate the possible effects of Beinaglutide on these risk factors.Research design and methods: In order to identify all randomized controlled trials that investigated the effects of Beinaglutide on cardiometabolic factors, a systematic search was conducted in the original databases using predefined keywords until July 2024. The pooled weighted mean difference (WMD) and 95% confidence intervals were computed using the random-effects model.Results: A quantitative meta-analysis results from seven studies with 872 participants showed that Beinaglutide has a significant lowering effect on weight (WMD: -3.74 kg; 95% CI: -5.03, -2.45), body mass index (BMI) (WMD:-1.64 kg/m2; 95% CI: -2.10, -1.17), waist circumference (WC) (WMD: -3.19 cm; 95% CI: -4.65 to -1.73), triglyceride (TG) levels (WMD: -0.14 mmol/l with; 95% CI: -0.25, -0.04), and systolic blood pressure (SBP) (WMD: -1.76 mm/Hg; 95% CI: -2.61, -0.91). In addition, body weight loss was greater in doses < 0.4 mg compared to doses ≥ 0.4 mg.Conclusions: The results of this meta-analysis show that Beinaglutide is effective in reducing parameters related to obesity, TG as well as SBP.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-10"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17446651.2025.2491404","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Considering the important role of obesity and related factors in different societies on increasing the burden of non-communicable diseases, in this review we will investigate the possible effects of Beinaglutide on these risk factors.

Research design and methods: In order to identify all randomized controlled trials that investigated the effects of Beinaglutide on cardiometabolic factors, a systematic search was conducted in the original databases using predefined keywords until July 2024. The pooled weighted mean difference (WMD) and 95% confidence intervals were computed using the random-effects model.

Results: A quantitative meta-analysis results from seven studies with 872 participants showed that Beinaglutide has a significant lowering effect on weight (WMD: -3.74 kg; 95% CI: -5.03, -2.45), body mass index (BMI) (WMD:-1.64 kg/m2; 95% CI: -2.10, -1.17), waist circumference (WC) (WMD: -3.19 cm; 95% CI: -4.65 to -1.73), triglyceride (TG) levels (WMD: -0.14 mmol/l with; 95% CI: -0.25, -0.04), and systolic blood pressure (SBP) (WMD: -1.76 mm/Hg; 95% CI: -2.61, -0.91). In addition, body weight loss was greater in doses < 0.4 mg compared to doses ≥ 0.4 mg.

Conclusions: The results of this meta-analysis show that Beinaglutide is effective in reducing parameters related to obesity, TG as well as SBP.

查看原文本刊更多论文

贝那鲁肽对肥胖及相关因素的影响：随机对照试验的系统回顾和荟萃分析。

背景：考虑到肥胖及其相关因素在不同社会中对增加非传染性疾病负担的重要作用，在本综述中，我们将探讨贝那鲁肽对这些危险因素的可能影响。研究设计与方法：为筛选所有研究贝那鲁肽对心脏代谢因子影响的随机对照试验，使用预设关键词对原始数据库进行系统检索，检索截止至2024年7月。采用随机效应模型计算合并加权平均差（WMD）和95%置信区间。结果：7项研究的872名参与者的定量荟萃分析结果显示，贝那鲁肽对体重有显著的降低作用(WMD: -3.74 kg；95% CI: -5.03, -2.45)，体重指数（BMI） (WMD:-1.64 kg/m2；95% CI: -2.10, -1.17)，腰围（WC） (WMD: -3.19 cm；95% CI: -4.65 ~ -1.73)，甘油三酯（TG）水平(WMD: -0.14 mmol/l；95% CI: -0.25, -0.04)和收缩压（SBP） (WMD: -1.76 mm/Hg；95% ci: -2.61, -0.91)。此外，与剂量≥0.4 mg相比，剂量< 0.4 mg的体重减轻更大。结论：本荟萃分析结果显示贝那鲁肽可有效降低肥胖、TG和收缩压相关参数。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Endocrinology & Metabolism ENDOCRINOLOGY & METABOLISM-

CiteScore

4.80

自引率

0.00%

发文量

期刊介绍： Implicated in a plethora of regulatory dysfunctions involving growth and development, metabolism, electrolyte balances and reproduction, endocrine disruption is one of the highest priority research topics in the world. As a result, we are now in a position to better detect, characterize and overcome the damage mediated by adverse interaction with the endocrine system. Expert Review of Endocrinology and Metabolism (ISSN 1744-6651), provides extensive coverage of state-of-the-art research and clinical advancements in the field of endocrine control and metabolism, with a focus on screening, prevention, diagnostics, existing and novel therapeutics, as well as related molecular genetics, pathophysiology and epidemiology.